Naringin Dihydrochalcone

Naringin dihydrochalcone is a synthetic flavonoid derivative created by hydrogenating naringin from citrus fruits. It functions primarily through cytochrome P450 enzyme inhibition and suppression of the inflammatory NF-κB signaling pathway.

Origin & History

Naringin dihydrochalcone is a synthetic flavonoid glycoside produced by hydrogenating naringin, a compound naturally found in citrus fruits like grapefruit. It is manufactured as a white to light yellow powder with >95% purity and is 500-700 times sweeter than sucrose.

Historical & Cultural Context

No historical or traditional medicine uses are documented for naringin dihydrochalcone. As a synthetic compound derived from citrus flavonoids, it lacks established use in traditional systems like Ayurveda or Traditional Chinese Medicine.

Health Benefits

• Antioxidant activity - exhibits antioxidant properties though specific clinical evidence not available
• CYP enzyme inhibition - shown to inhibit cytochrome P450 enzymes in laboratory studies
• NF-κB signaling suppression - associated with suppression of inflammatory NF-κB pathway in preclinical research
• Potential anti-inflammatory effects - targets MAPK/ERK and PI3K/Akt/mTOR pathways in laboratory studies
• Membrane transporter modulation - interacts with transporters like BCRP and CFTR channels in preliminary research

How It Works

Naringin dihydrochalcone inhibits cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, affecting drug metabolism pathways. The compound suppresses nuclear factor-kappa B (NF-κB) signaling, reducing inflammatory cytokine production. Its dihydrochalcone structure enhances stability and bioavailability compared to the parent naringin compound.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses were identified in the available research. Current evidence is limited to chemical characterization and preliminary laboratory studies on cellular pathways.

Clinical Summary

Current evidence for naringin dihydrochalcone comes primarily from laboratory and preclinical studies rather than human clinical trials. In vitro studies have demonstrated significant cytochrome P450 enzyme inhibition with IC50 values in the micromolar range. Animal studies show anti-inflammatory effects through NF-κB pathway suppression, but specific dosages and clinical translation remain unclear. Human clinical data is lacking, making it difficult to establish therapeutic efficacy or optimal dosing protocols.

Nutritional Profile

Naringin dihydrochalcone (naringin DC) is a semi-synthetic flavonoid derivative (C₂₇H₃₄O₁₅, MW ~582.54 g/mol) produced by catalytic hydrogenation of naringin, a naturally occurring flavanone glycoside found in citrus fruits. It is not a nutritional food source but rather a single bioactive compound used primarily as a high-intensity sweetener (approximately 300–1,800 times sweeter than sucrose, depending on concentration and matrix). Key biochemical characteristics: • Classification: Dihydrochalcone glycoside (flavonoid subclass). • Core bioactive structure: Dihydrochalcone aglycone backbone with a neohesperidose (rhamnose-glucose) sugar moiety attached at the 2'-position. • Caloric contribution: Essentially negligible at typical usage levels (employed at mg quantities due to extreme sweetness potency). • No significant macronutrient content (no protein, fat, or dietary fiber). • No meaningful vitamin or mineral content. • Bioactive properties stem from the polyphenolic hydroxyl groups on the aromatic rings, which confer antioxidant capacity (ORAC and DPPH radical scavenging activity documented in vitro). • Bioavailability notes: Oral bioavailability is limited by extensive first-pass metabolism; the neohesperidose sugar is cleaved by intestinal microflora (primarily by α-rhamnosidase and β-glucosidase), yielding the aglycone phloretin and free sugars. Phloretin, the primary metabolite, undergoes further glucuronidation and sulfation in the liver. Absorption is primarily in the colon following microbial deglycosylation, resulting in delayed Tmax. Estimated oral bioavailability of intact compound is low (<5–10%), though colonic metabolites (phloretin glucuronides) circulate systemically. • Solubility: Moderately soluble in water (~1 g/L at 25°C); solubility improves in alkaline conditions and ethanol-water mixtures. • Approved as a food additive/sweetener (E959) in the European Union and several other jurisdictions; ADI set at 0–5 mg/kg body weight/day by JECFA. • Contains no known allergenic proteins, gluten, or common food allergens. • Residual naringin content may be present in commercial preparations depending on hydrogenation completeness (typically <2%).

Preparation & Dosage

No clinically studied dosage ranges have been established for naringin dihydrochalcone. Commercial products are available as powder with >95% purity. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Quercetin, Hesperidin, Bioflavonoids, Citrus Extract

Safety & Interactions

Naringin dihydrochalcone may interact with medications metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9 substrates. This could potentially alter blood levels of drugs including certain statins, blood thinners, and immunosuppressants. Common side effects and contraindications have not been well-established due to limited human studies. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data.